2023
Outcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed?
Shah N, Ngwube A, Jacobsohn D, Shenoy S. Outcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed? Blood 2023, 142: 2185. DOI: 10.1182/blood-2023-190524.Peer-Reviewed Original ResearchDisease-free survivalSickle cell diseaseSevere sickle cell diseaseUnrelated donor transplantsGVHD prophylaxisAllogeneic transplantationCell diseaseChronic GVHDDonor transplantsMarrow transplantationGrade 2Unrelated donor stem cell transplantationAllogeneic T cell proliferationDonor stem cell transplantationUnrelated donor marrow transplantationCalcineurin inhibitor useHost disease (GVHD) prophylaxisRelated donor transplantsSevere chronic GVHDSuccessful allogeneic transplantationGroup 1 patientsPhase II trialImmune suppression therapyStem cell transplantationHuman leucocyte antigen
2021
Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?
Shah N, Krishnamurti L. Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks? Hematology 2021, 2021: 190-195. PMID: 34889371, PMCID: PMC8791135, DOI: 10.1182/hematology.2021000322.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantVaso-occlusive pain episodesSickle cell diseaseCell diseaseDonor hematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantHuman leukocyte antigen identicalSevere sickle cell diseaseBenefits of HLAAcute chest syndromeHLA-identical siblingsStem cell transplantYears of ageAge-appropriate activitiesChest syndromePain crisisPain episodesFebrile episodesCell transplantMedical conditionsMale childrenFemale childrenPatientsCase 2Case 1
2020
Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.
Ngwube A, Shah N, Godder K, Jacobsohn D, Hulbert ML, Shenoy S. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Advances 2020, 4: 3894-3899. PMID: 32813873, PMCID: PMC7448594, DOI: 10.1182/bloodadvances.2020002236.Peer-Reviewed Original ResearchConceptsSevere sickle cell diseaseReduced-intensity conditioningSickle cell diseaseUnrelated donorsChronic GVHDCell diseaseBone marrowUnrelated donor stem cell transplantationDonor stem cell transplantationReversible posterior encephalopathy syndromeCord blood recipientsHost disease (GVHD) prophylaxisDisease-free survivalOne-year incidenceBone marrow recipientsStem cell transplantationLonger durationPosterior encephalopathy syndromePhase 1 portionCell transplantation trialsClinical trial settingsT cell costimulationPhase 2 portionStem cell sourceAcute GVHD
2019
Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)
Ngwube A, Shah N, Jacobsohn D, Dela Ziga E, Shenoy S. Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD). Blood 2019, 134: 370. DOI: 10.1182/blood-2019-126405.Peer-Reviewed Original ResearchSevere sickle cell diseaseEvent-free survivalHost disease preventionAntigen-presenting cellsSickle cell diseaseURD-SCTLower incidenceAcute GVHDChronic GVHDGVHD prophylaxisAcute graftOverall survivalCell transplantationCell diseaseSevere SCDT cell co-stimulation blockadeUnrelated donor hematopoietic cell transplantationUnrelated donor stem cell transplantationDisease preventionAcute chest syndrome episodesDonor stem cell transplantationUnrelated donor marrow transplantationVaso-occlusive pain crisesAcute GVHD incidenceAcute GVHD prevention